Short Interest in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTW) Decreases By 66.5%

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTW) was the target of a large drop in short interest during the month of July. As of July 31st, there was short interest totaling 49,126 shares, a drop of 66.5% from the July 15th total of 146,438 shares. Based on an average daily trading volume, of 92,986 shares, the days-to-cover ratio is presently 0.5 days.

Rocket Pharmaceuticals Trading Down 22.2%

Shares of NASDAQ RCKTW opened at $0.00 on Friday. Rocket Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $0.08.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, life-transforming gene therapies for rare pediatric diseases. The company’s research and development activities center on inherited genetic disorders, leveraging both lentiviral and adeno-associated virus (AAV) platforms to deliver corrective genes. Rocket’s lead programs include treatments for conditions such as Fanconi anemia, leukocyte adhesion deficiency-I (LAD-I), Danon disease and mucopolysaccharidosis type IIIA (MPS IIIA), each of which represents a high unmet medical need in the pediatric population.

Founded in 2015, Rocket Pharmaceuticals went public in 2018 and trades on the Nasdaq under the ticker symbol RCKTW.